Another turn of events in the eciting lives of RBM shareholders
Response Biomedical Corp.
8855 Northbrook Court
Burnaby, BC Canada V5J 5J1
NEWS RELEASE
RESPONSE BIOMEDICAL RESCINDS WITHDRAWAL
Vancouver, British Columbia, September 10, 2001. Response Biomedical Corp.
(RBM: CDNX), developer of the RAMP* diagnostic system, today announced that,
after further discussion with the US Food and Drug Administration, the
Company has rescinded its voluntary withdrawal of its recent 510(k)
submission.
"We are pleased that the FDA is willing to meet with the Company and provide
guidance regarding the submission," stated Bill Radvak, President and Chief
Executive Officer of Response Biomedical. Mr. Radvak also stated that the
Company intends to meet with the FDA as soon as possible, as well as provide
additional information to the Agency.
"We remain confident in the RAMP System and its ability to achieve
regulatory clearance," added Mr. Radvak. "Furthermore, we will continue to
move forward with our business development and finance initiatives, and work
to restore shareholder value which was negatively impacted by the temporary
withdrawal of the 510(k)."
About Response Biomedical Corp.
Response Biomedical develops quantitative, diagnostic tests for use with its
proprietary RAMP Reader that are intended to be used for clinical, STAT-lab
and point-of-care applications. The RAMP System is expected to reduce the
cost of healthcare by allowing rapid and easy-to-use medical tests to be
performed in hospitals, clinics, laboratories and physicians' offices
worldwide. The Company's platform technology has the potential to be used
with more than 250 medical tests that are currently performed by traditional
laboratory methods. Response Biomedical's shares are listed on the Canadian
Venture Exchange under the trading symbol "RBM". For further information,
visit the Company's website at www.responsebio.com
-30-
The Canadian Venture Exchange has not reviewed and does not accept
responsibility for the adequacy of the content of the information contained
herein. The statements made in this press release may contain certain
forward-looking statements that involve a number of risks and uncertainties.
Actual events or results may differ from the Company's expectations.
Company Contacts:
John Gomez
Corporate Communications Manager
Response Biomedical Corp.
Tel (604) 681-4101
Fax (604) 412-9830
Email: jgomez@responsebio.com
Bill Radvak
President & CEO
Response Biomedical Corp.
Tel (604) 681-4101
Fax (604) 412-9830
Email: bradvak@responsebio.com |
